CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these condensed consolidated interim financial statements they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's auditors have not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(Unaudited - Expressed in Canadian Dollars)

	Note	August 31, 2022 \$	November 30, 2021 \$
ASSETS			
Cash		2,461,665	545,976
Advances receivable	11(b)	16,500	16,500
GST receivable	. ,	141,491	67,665
Prepaid expenses	3	78,684	1,153,977
Investments in marketable securities	4	373,900	634,846
Private investments, at fair value through profit or loss	5	59,755,080	54,755,080
Loans receivable	6	1,080,648	2,423,922
Deferred share issue costs	9(c)		29,448
TOTAL ASSETS		63,907,968	59,627,414
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities		1,003,560	668,153
Current portion on loans payable	7	7,354,699	8,427,999
Credit facility	8	38,881,412	33,205,342
Total current liabilities		47,239,671	42,301,494
Non-current liabilities			
Loans payable	7	2,451,567	8,055,724
Amara economic interest	9(b)	1,338,133	
Total non-current liabilities		3,789,700	8,055,724
TOTAL LIABILITIES		51,029,371	50,357,218
SHAREHOLDERS' EQUITY			
Share capital	9	54,964,191	44,921,827
Subscriptions received in advance		51,501,151	239,085
Share-based payments reserve		12,334,428	10,908,759
Commitment to issue common shares	5	41,620,369	41,620,369
Contributed surplus	7(a)	187,828	187,828
Deficit	. ()	(96,228,219)	(88,607,672)
TOTAL SHAREHOLDERS' EQUITY		12,878,597	9,270,196
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		63,907,968	59,627,414

Nature of Operations and Going Concern - Note 1

Events after the Reporting Period - Note 14

These condensed consolidated interim financial statements were approved for issue by the Board of Directors on October 31, 2022 and are signed on its behalf by:

/s/ Marc Aneed	/s/ Patrick Dunn
Marc Aneed	Patrick Dunn
Director	Director

EAT WELL INVESTMENT GROUP INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)

(Unaudited - Expressed in Canadian Dollars)

	Three Months I		inded August 31	Nine Months E	Nine Months Ended August 31	
	Note	2022	2021	2022	2021	
		\$	\$	\$	\$	
Net investment gain (loss)						
Realized loss on sale of investments		-	(585,525)	-	(817,106)	
Unrealized gain on investments held	-	4,693,880	769,494	4,739,054	2,071,062	
	-	4,693,880	183,969	4,739,054	1,253,956	
Expenses (Income)						
Accounting and administration	11(a)	128,144	12,500	445,954	43,800	
Audit	(-)	27,500	-	142,500	27,500	
Corporate development		238,016	_	765,337		
Corporate finance fee	9(c)		_	50,000	_	
Director and officer compensation and benefits	11(a)(i)	523,961	187,127	1,547,138	228,471	
Discount on loans payable	7(b)	525,701	107,127	1,5 17,130	220,171	
Foreign exchange	7(0)	205,377	88,784	219,701	90,326	
Insurance		43,470	00,704	104,864	90,320	
	10	950,799	561,617	4,379,386	561,617	
Interest expense and financing costs Interest income	10		,			
Investor relations		(22,064)	(9,933)	(120,685)	(28,066)	
	11(-)('-)	170,032	472.712	510,096	500.012	
Legal	11(a)(iv)	254,305	473,713	708,510	509,012	
Marketing		150,435	-	727,514	-	
Media		7,500	-	116,209	-	
Office		10,998	11,664	49,580	15,824	
Professional fees		279,335	43,310	447,703	118,077	
Regulatory		27,069	2,250	40,021	9,493	
Rent		4,905	-	10,216	-	
Salaries and benefits		51,174	31,909	193,428	31,909	
Share-based compensation	9	521,025	2,132,267	1,797,854	4,650,067	
Shareholder costs		40,965	5,782	50,362	8,132	
Transaction costs on private investments		-	11,939,012	-	11,939,012	
Transfer agent		2,426	2,236	24,136	4,710	
Travel		30,647	-	86,776	-	
Website design and maintenance	_	920	79,410	24,870	80,730	
	_	3,646,939	15,561,648	12,321,470	18,290,614	
N.A						
Net income (loss) and	J	1.046.041	(15 277 (70)	(7.500.416)	(17.02((50)	
comprehensive income (loss) for the period	a <u>-</u>	1,046,941	(15,377,679)	(7,582,416)	(17,036,658)	
Net income (loss) per share - basic and diluted	d	\$0.01	\$(0.16)	\$(0.05)	\$(0.20)	
· · · · · ·	•					
Weighted average number of common shares outstanding - basic and diluted		155,275,330	97,541,664	143,484,967	85,467,447	

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Unaudited - Expressed in Canadian Dollars)

	Nine Months Ended August 31, 2022								
	Share	Capital							
	Number of Shares	Amount \$	Special Warrants \$	Subscriptions Received in Advance \$	Share-Based Payments Reserve \$	Commitment to Issue Common Shares \$	Contributed Surplus \$	Deficit \$	Total Shareholders' Equity \$
Balance at November 30, 2021	126,808,154	44,921,827	-	239,085	10,908,759	41,620,369	187,828	(88,607,672)	9,270,196
Common shares issued for:									
Cash - private placement	6,690,666	3,679,867	-	-	-	-	-	-	3,679,867
Cash - exercise of warrants	12,134,231	1,820,135	-	(239,085)	-	-	_	_	1,581,050
Cash - special warrants	-	-	5,100,000	-	-	-	-	-	5,100,000
Exercise of special warrants	10,403,995	5,100,000	(5,100,000)						-
Redemption of RSUs	1,000,000	550,000	-	-	(550,000)	-	-	-	-
Share issue costs	-	(938,597)	-	-	177,815	-	-	-	(760,782)
Repurchase of common shares	(468,000)	(169,041)	-	-	-	-	-	(38,131)	(207,172)
Share-based compensation:									
Share options	-	-	-	-	367,963	-	-	-	367,963
RSUs	-	-	-	-	1,429,891	-	-	-	1,429,891
Net loss for the period								(7,582,416)	(7,582,416)
Balance at August 31, 2022	156,569,046	54,964,191			12,334,428	41,620,369	187,828	(96,228,219)	12,878,597

	Nine Months Ended August 31, 2021					
	Share C	Share Capital				
	Number of Shares	Amount \$	Share-Based Payments Reserve \$	Deficit \$	Total Shareholders' Equity \$	
Balance at November 30, 2020	45,595,354	24,865,933	4,111,318	(23,942,121)	5,035,130	
Common shares issued for:						
Cash - private placement	40,000,000	3,000,000	-	-	3,000,000	
Cash - exercise of warrants	4,750,000	712,500	-	-	712,500	
Redemption of DSUs	125,000	56,875	(56,875)	-	-	
Finders' fees	3,550,333	190,196	76,079	-	266,275	
Shares for debt	60,000	33,000	-	-	33,000	
Private investments	3,741,969	2,394,860	-	-	9,739,631	
Transaction costs	17,482,831	11,189,012	-	-	3,844,241	
Credit facility	500,000	320,000	-	=	320,000	
Share issue costs	=	(291,961)	-	-	(291,961)	
Repurchase of common shares	(467,500)	(154,925)	-	(110,158)	(265,083)	
Share-based compensation:						
Share options	-	-	2,064,509	-	2,064,509	
RSUs	=	-	2,205,578	=	2,205,578	
DSUs	-	-	42,730	-	42,730	
Transfer of DSUs to RSUs	-	-	337,250	-	337,250	
Warrants	=	-	505,000	=	505,000	
Transfer on exercise of warrants	-	5,000	(5,000)	-	=	
Net loss for the period	<u> </u>			(17,036,658)	(17,036,658)	
Balance at August 31, 2021	115,337,987	42,320,490	9,280,589	(41,088,937)	10,512,142	

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited - Expressed in Canadian Dollars)

	Nine Months Ended		
	August 31,	August 31,	
	2022	2021 \$	
	\$	3	
Operating activities			
Net loss for the period	(7,582,416)	(17,036,658)	
Adjustments for:			
Interest income	(107,622)	(226)	
Realized loss on sale of investments	-	817,106	
Unrealized gain on investments held	(4,739,054)	(2,071,062)	
Share-based compensation	1,797,854	4,650,067	
Interest expense and financing costs	4,095,011	285,000	
Transaction costs	-	11,189,012	
Foreign exchange	408,979	65,353	
	(6,127,248)	(2,101,408)	
Adjustments for:			
Advances receivable	-	(13,500)	
GST receivable	(73,826)	(30,236)	
Prepaid expenses	1,075,293	(376)	
Accounts payable and accrued liabilities	335,407	579,543	
Proceeds from sale of investments in marketable securities	-	1,372,759	
Payments made on private investments	-	(2,918,378)	
Advances on loans receivable	(484,624)	(315,425)	
Repayment on loans receivable	1,959,000		
Net cash used in operating activities	(3,315,998)	(3,427,021)	
Financing activities			
Issuance of common shares	10,390,365	3,712,500	
Amara economic interest	1,338,133	-	
Share issue costs	(760,782)	(25,686)	
Repurchase of common shares	(207,172)	(265,083)	
Repayment towards loans payable	(7,884,518)	-	
Advance on credit facility	4,990,000	_	
Interest paid on credit facility	(2,634,339)		
Net cash provided by financing activities	5,231,687	3,421,731	
Net change in cash	1,915,689	(5,290)	
Cash at beginning of period	545,976	3,542,588	
Cash at end of period	2,461,665	3,537,298	

Supplemental cash flow information - See Note 13

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

1. Nature of Operations and Going Concern

The Company is a publicly-traded Canadian based venture capital firm that is focused on investments in early stage companies with high growth potential. On August 30, 2021 the Company changed its name from Rockshield Capital Corp. to Eat Well Investment Group Inc. to more appropriately reflect the Company's investment policy to focus on the agribusiness, foodtech and plant-based food industries. The Company's common shares trade on the Canadian Securities Exchange ("CSE") under the trading symbol "EWG". The Company's principal office is located at #1305 - 1090 West Georgia Street, Vancouver, British Columbia, V6E 3V7.

During the nine months ended August 31, 2022 the Company recorded a net loss of \$7,582,416 and, as at August 31, 2022, had a cash balance of \$2,461,665 and current liabilities of \$47,239,671. The Company will need to secure additional funding to meet ongoing levels of corporate overheads, retire amounts due on the Company's investments in plant-based companies and amounts loaned under the credit facility and repay indebtedness as they come due. The Company intends to secure long-term financing and/or raise additional capital from the sale of additional common shares or other equity instruments. Whether the Company can raise sufficient capital is uncertain. These material uncertainties may cast significant doubt upon the Company's ability to continue as a going concern. See also Note 14.

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business operations for the foreseeable future and do not include any adjustments relating to the recoverability and classification of recorded asset amounts nor to the amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern or be unable to realize its assets or discharge its liabilities in the normal course of business. Such adjustments can be material.

During March 2020 the World Health Organization characterized COVID-19 as a pandemic. COVID-19 has had a material adverse impact on global economies. In order to combat the spread of COVID-19 governments worldwide, including Canada, enacted emergency measures including travel restrictions, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. Determining the impact of COVID-19 on the valuation of the Company's investment portfolio required significant judgement given the amount of uncertainty regarding the long-term impact of COVID-19. The ultimate impact of COVID-19 on the financial results of the Company and its investee companies will depend on future developments, including the duration and spread of the pandemic and related advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain and difficult to predict. If the financial markets and/or the overall economy are impacted for a period significantly longer than currently implied by the markets, the financial results of the Company, including the fair value of its corporate investments, may be materially adversely affected.

2. Basis of Preparation

Statement of Compliance

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting ("IAS 34"), as issued by the International Accounting Standards Board ("IASB"), and its interpretations, using accounting policies consistent with International Financial Reporting Standards ("IFRS"). The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended November 30, 2021, which have been prepared in accordance with IFRS as issued by the IASB and interpretations of the IFRS Interpretations Committee ("IFRIC"). The accounting policies followed in these condensed consolidated interim financial statements are consistent with those applied in the Company's consolidated financial statements for the year ended November 30, 2021.

Basis of Measurement

These condensed consolidated interim financial statements have been prepared on a historical cost basis except for the revaluation of certain financial assets and financial liabilities to fair value. These condensed consolidated interim financial statements are presented in Canadian dollars unless otherwise noted.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

3. Prepaid Expenses

	August 31, 2022	November 30, 2021
	\$	\$
Marketing programs	50,000	578,014
Investor relations programs	-	510,096
Media programs	2,500	-
Other	26,184	65,867
	78,684	1,153,977

4. Investments in Marketable Securities

The Company's investments in marketable securities include common shares and other equity instruments of Canadian and U.S. companies that are listed on various Canadian stock exchanges or the OTCQB. The Company also has investments in common shares of private companies which plan to publicly list their shares.

Management has designated its investments in common shares and warrants of companies as "investments in equity/debt instruments" with the change in fair value recognized in profit or loss. The carrying values of the listed common shares and warrants have been directly referenced to published price quotations in an active market. The carrying values of equity and debt investments in unlisted private companies are valued at fair value using non-observable market inputs based on specific company information and general market conditions. The carrying values of the unlisted warrants are valued at fair value using the Black-Scholes option pricing model.

During the nine months ended August 31, 2021 the Company sold certain of its investments in marketable securities for proceeds totalling \$1,372,759 and recognized a loss of \$817,106.

During the nine months ended August 31, 2022 the Company recorded an unrealized loss of \$260,947 (2021 - gain of \$2,071,062) on investments in marketable securities held.

5. Private Investments, at Fair Value Through Profit or Loss

	Cost \$	Value \$
Belle Pulses Ltd. ("Belle Pulses")	30,000,000	35,000,000
Sapientia Technology LLC ("Sapientia")	10,374,680	10,374,680
Pata Foods Inc. ("Amara")	14,380,400	14,380,400
	54,755,080	59,755,080

Fair

Investments in Belle Pulses and Sapientia

On April 23, 2021 the Company entered into a binding letter of intent with Novel Agri-Technologies Inc. ("Novel") pursuant to which the Company agreed to assume Novel's contractual rights to acquire 100% of two private arm's length plant-based food companies, Belle Pulses and Sapientia (the "Initial Acquisitions").

On July 30, 2021 the Company completed the Initial Acquisitions. The Company paid \$30,000,000 cash to acquire Belle Pulses. Part of the cash consideration, \$29,750,000, was advanced directly to the vendors by the Cortland Credit Lending Corporation (Note 8). The consideration for the acquisition of Sapientia was the issuance of 3,741,969 common shares of the Company, at a fair value of \$2,394,860, and the obligation to make cash payments totalling US \$6,400,000. See also Note 7(a).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

5. Private Investments, at Fair Value Through Profit or Loss (continued)

In connection with the closing of the Initial Acquisitions the Company paid \$750,000 and issued a total of 11,476,205 common shares of the Company, at a fair value of \$7,344,771, to Novel for total consideration of \$8,094,771 (the "Novel Consideration") and issued a total of 6,006,626 common shares of the Company, at a fair value of \$3,844,241, to finders (the "Finders' Shares"). In addition, the Company has agreed to pay Novel net profits interest shares in the Initial Acquisitions convertible up to an additional 65,031,826 common shares of the Company. These net profits interest shares were assigned a fair value of \$41,620,369 (the "NPI Consideration"). The Novel Consideration, the Finders' Shares amounts and the NPI Consideration, totaling \$53,559,381, have been expensed as transaction costs incurred for the Initial Acquisitions during fiscal 2021.

Following closing of the Initial Acquisitions, certain principals of Novel have been appointed as officers of the Company to provide ongoing investment oversight services in respect of the Company's investments.

Investment in Amara

On November 2, 2021, the Company entered into a purchase agreement (the "Series A Preferred Stock Purchase Agreement") pursuant to which the Company acquired 2,047,299 series A preferred shares in the capital of Amara (the "Amara Series A Shares"), representing 51% equity ownership of Amara on a fully diluted as-converted basis (the "Initial Amara Investment"), together with an option to acquire an additional 29% of the shares of Amara from certain other shareholders of Amara, for an aggregate cash purchase price of US \$29,000,000 (the "Amara Share Purchase Option"), which (if exercised) would result in the Company having an 80% equity ownership of Amara on a fully diluted as-converted basis.

The consideration for the Initial Amara Investment included a cash payment of US \$1,000,000 and the issuance by the Company of a promissory note in favor of Amara in the principal amount of US \$10,600,000 (the "Amara Promissory Note"). See also Note 7(b).

The Amara Series A Shares include certain rights that rank in preference to the currently outstanding shares of Amara, including in respect to dividends (when and if declared), liquidation events, and mergers and other corporate transactions. The Amara Series A Shares will be convertible by the holders thereof at any time into common shares in the capital of Amara. On the seventh anniversary of the closing of the Initial Amara Investment, the Company may redeem its Amara Series A Shares in exchange for the original issue price (plus accrued and unpaid dividends) in the event Amara does not complete a liquidity event or qualified initial public offering by that time.

6. Loans Receivable

	Sapientia \$	Belle Pulses \$	Total \$
Principal			
Balance at November 30, 2021	383,760	2,000,000	2,383,760
Advances received	484,624	-	484,624
Advances repaid	-	(1,959,000)	(1,959,000)
Foreign exchange adjustment	23,164		23,164
Balance at August 31, 2022	891,548	41,000	932,548
Interest			
Balance at November 30, 2021	1,806	38,356	40,162
Interest	9,788	97,834	107,622
Foreign exchange adjustment	316		316
Balance at August 31, 2022	11,910	136,190	148,100

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

6. Loans Receivable (continued)

The Sapientia loan bears interest at a rate of 1.87% per annum and is repayable with accrued interest on August 17, 2023. During the nine months ended August 31, 2022 the Company recorded interest income of \$9,788 (2021 - \$226). See also Note 14(iv).

The Belle Pulses loan bears interest at 10% per annum and is repayable with interest on September 22, 2023. During the nine months ended August 31, 2022 the Company recorded interest income of \$97,834. See also Note 14(v).

7. Loans Payable

·	Sapientia \$	Amara \$	Total \$
Cash obligations on investments	7,979,820	14,380,400	22,360,220
Payments made	(3,754,380)	(1,238,180)	(4,992,560)
Discount - contribution benefit	(187,828)	-	(187,828)
Additional amount on extension	148,315	-	148,315
Loss on loan modification	25,117	-	25,117
Below market interest rate discount	-	(1,447,088)	(1,447,088)
Interest expense accrued	176,561	87,737	264,298
Foreign exchange adjustment	(59,631)	372,880	313,249
Balance at November 30, 2021	4,327,974	12,155,749	16,483,723
Payments made	(4,509,968)	(3,374,550)	(7,884,518)
Interest expense accrued	136,982	799,745	936,727
Foreign exchange adjustment	45,012	225,322	270,334
Balance at August 31, 2022	-	9,806,266	9,806,266
Less current portion		(2,451,567)	(2,451,567)
Non-current portion		7,354,699	7,354,699

(a) The Company was obligated to pay an initial US \$6,400,000 on the acquisition of Sapientia, of which US \$1,000,000 was paid on closing and US \$1,000,000 paid on August 31, 2021. The remaining US \$4,400,000 consideration was to be paid as to US \$2,000,000 on or before October 31, 2021 and US \$2,400,000 on or before December 31, 2021. On October 25, 2021 the Company negotiated an extension and revision of the remaining US \$4,400,000 consideration. Under the revised payment terms, the Company agreed to pay a revised total of US \$4,520,000 (the "Revised Sapientia Obligation"), of which US \$1,000,000 was paid during fiscal 2021 and the remaining US \$3,520,000 paid during the nine months ended August 31, 2022. The incremental \$148,315 (US \$120,000) consideration was expensed in fiscal 2021 as part of interest expense and financing costs.

The holders of the Sapientia obligations are shareholders of the Company. The Company determined that the rate implicit in the loan is at a market rate of 10% per annum. Accordingly, during fiscal 2021 the Company recorded an initial benefit of the below-market interest rate loan of \$187,828 to contributed surplus. During the nine months ended August 31, 2022, interest expense of \$136,982 was recognized in the condensed consolidated interim statement of loss and comprehensive loss.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

7. Loans Payable (continued)

(b) The Amara Promissory Note accrues interest at a rate of 0.18% per annum and is repayable in scheduled quarterly instalments of US \$1,325,000 principal and accrued interest for a period of 24 months from the date of issuance, subject to the Company's right to accelerate payment at any time without penalty and the Company's obligation to prepay the full amount of the Amara Promissory Note in the event the Company completes any transaction (including any issuance of debt in excess of US \$50,000,000) resulting in the Company's receipt of net proceeds in excess of US \$30,000,000. The Company's obligations under the Promissory Note are secured by a share pledge in respect of certain of the Amara Series A Shares issued to the Company pursuant to the Initial Amara Investment. During the nine months ended August 31, 2022 the Company paid US \$2,662,526 (US \$2,650,000 principal and US \$12,526 interest expense) in respect of the Amara Promissory Note.

During the nine months ended August 31, 2022, interest expense of \$799,745 (2021 - \$nil) was recognized in the condensed consolidated interim statement of loss and comprehensive loss.

The Company determined that the rate implicit in the loan is at a market rate of 10% per annum. Accordingly, the Company recorded an initial benefit of the below-market interest rate loan of \$1,447,088 to profit or loss during fiscal 2021.

See also Note 14(iii).

8. Credit Facility

	August 31, 2022	November 30, 2021
	\$	\$
Principal amounts borrowed	38,490,000	33,500,000
Unamortized debt issue	-	(570,000)
Accrued interest	391,412	275,342
	38,881,412	33,205,342

The Company has obtained a revolving line of credit (the "Credit Facility") with Cortland Credit Lending Corporation ("Cortland") to borrow a maximum principal amount not to exceed \$40,000,000. Outstanding principal amounts borrowed under the Credit Facility bears interest at a rate per annum equal to the greater of 7.55% above prime or 10% and shall be paid monthly. During the nine months ended August 31, 2022 the Company has incurred interest of \$2,750,409 (2021 - \$276,617) of which \$391,412 was outstanding at August 31, 2022. The Credit Facility is currently scheduled to mature on November 30, 2022, but may be extended for thirty days or by agreement.

The Company has incurred financing transaction costs totalling \$1,710,000 of which \$1,140,000 was expensed during fiscal 2021 and the remaining \$570,000 was expensed during the nine months ended August 31, 2022.

During the nine months ended August 31, 2022 the Company paid Cortland a commitment fee of \$48,750 to increase the revolving line of credit. In addition the Company incurred a financing facilitation fee of \$73,500 associated with the credit facility from an arms-length party.

9. Share Capital

(a) Authorized Share Capital

The Company's authorized share capital consisted of an unlimited number of common shares without par value. All issued common shares are fully paid.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

9. Share Capital (continued)

(b) Reconciliation of Changes in Share Capital

Nine Months Ended August 31, 2022

On February 15, 2022 the Company completed a non-brokered private placement with Nurture Healthy Food LLP ("Nurture Healthy Food" or "NHF") a wholly-owned subsidiary of Nurture Capital LLC of 6,690,666 units at a price of \$0.75 per unit for gross proceeds of \$5,018,000. Each unit was comprised of one common share of the Company and one half of one common share purchase warrant. Each whole warrant has an exercise price of \$1.00 per share that is exercisable on or before February 15, 2025.

In connection with the private placement the Company has entered into a purchase agreement (the "Purchase Agreement") with NHF, pursuant to which the Company has sold to NHF an economic interest (the "Amara Economic Interest") in the shares of Amara. The Amara Economic Interest provides NHF with the right to receive 8% of the net proceeds or other property (after having deducted the Company's investment cost base for its equity interest in Amara) received by the Company upon the occurrence of: (i) a liquidation event in respect of Amara (including a merger of Amara or any sale of all or a portion of the overall equity interest in Amara held by the Company); and (ii) an initial public offering of the shares of Amara or other public listing event in respect of Amara, all pursuant to the Purchase Agreement. In addition, NHF is entitled to 8% of any dividend declared and paid by Amara to the Company. The Company has determined the fair value of the Amara Economic Interest to be \$1,338,133, which has been bifurcated from the private placement.

The Company has incurred \$55,695 in legal and filing costs associated with the private placement.

Fiscal 2021

(i) On January 15, 2021 the Company completed a non-brokered private placement of 40,000,000 units at \$0.075 per unit for total proceeds of \$3,000,000. Each unit comprised one common share and one share purchase warrant entitling the holder to purchase an additional common share at a price of \$0.15 per share on or before January 15, 2023. Certain directors and officers of the Company acquired a total of 4.133,334 units of the private placement.

The Company also issued 3,550,333 finders' units having the same terms as the private placement units. The units were recorded at a fair value of \$266,275.

The Company incurred a total of \$25,686 for filing fees and legal costs.

(ii) The Company issued 60,000 common shares for an ascribed value of \$33,000 in settlement of outstanding accounts payable.

(c) Special Warrants

On December 23, 2021 the Company completed a brokered private placement of 9,272,727 of special warrants (the "Special Warrants") of the Company at a price of \$0.55 per Special Warrant for \$5,100,000 gross proceeds. Each Special Warrant converted into 1.122 units per Special Warrant for a total of 10,403,995 units.

The Agents received \$241,921 for commissions and \$35,700 for syndication fees. In addition, the Company granted the Agents 508,043 non-transferable compensation warrants (the "Compensation Warrants"). Each Compensation Warrant entitles the holder thereof to purchase one unit (a "Compensation Warrant Unit") at an exercise price per Compensation Warrant Unit of \$0.55 until December 23, 2024. The fair value of the Compensation Warrants has been estimated using the Black-Scholes Option Pricing Model. The assumptions used were as follows: risk-free interest rate of 1.16%; expected volatility of 104%; an expected life of three years; and a dividend yield of 0%. The value assigned to the Compensation Warrants was \$177,815. The weighted average fair value of the Compensation Warrants issued was \$0.35 per warrant.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

9. Share Capital (continued)

The Company has incurred \$427,466 for legal and filing costs associated with the private placement, of which the Company had recorded \$29,448 at November 30, 2021.

The Company also paid a \$50,000 corporate finance fee which has been expensed.

On April 25, 2022 the Special Warrants were exercised, for no additional consideration, into an aggregate of 10,403,995 units, consisting of 10,403,995 common shares of the Company and 5,201,995 common share purchase warrants. Each warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$0.75 per share until December 23, 2024.

(d) Normal Course Issuer Bid

On April 30, 2021 the Company filed a normal course issuer bid (the "NCIB") which authorized the Company to repurchase for cancellation up to 4,473,534 common shares. The NCIB expired on April 30, 2022. During the nine months ended August 31, 2022 the Company repurchased a total of 301,500 common shares for \$169,627 cash consideration under the this NCIB.

On June 21, 2022 the Company filed a new NCIB ("Second NCIB") which authorizes the Company to repurchase for cancellation up to 7,686,777 common shares. The Second NCIB commenced June 27, 2022 and expires June 26, 2023. During the nine months ended August 31, 2022 the Company repurchased a total of 166,500 common shares for \$37,545 cash consideration under the Second NCIB.

See also Note 14(i).

(e) Warrants

A summary of the number of common shares reserved pursuant to the Company's outstanding warrants at August 31, 2022 and 2021 and the changes for the nine months ended on those dates is as follows:

	2022		2021		
	Number	Weighted Average Exercise Price \$	Number	Weighted Average Exercise Price \$	
Balance, beginning of period	29,093,666	0.16	-	-	
Issued	8,547,328	0.85	44,550,333	0.16	
Exercised	(12,134,231)	0.15	(4,750,000)	0.15	
Balance, end of period	25,506,763	0.40	39,800,333	0.16	

The following table summarizes information about the number of common shares reserved pursuant to the Company's warrants outstanding and exercisable at August 31, 2022:

Number	Exercise Price \$	Expiry Date		
15,959,435	0.15	January 15, 2023		
5,201,995	0.75	December 23, 2024		
3,345,333	1.00	February 15, 2025		
1,000,000	0.58	July 30, 2026		
25,506,763				

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

9. Share Capital (continued)

(f) Share Option Plan

On February 26, 2021 the Company's Board of Directors approved a rolling share option plan (the "Rolling Share Option Plan") as a replacement to the Company's Fixed Share Option Plan. Under the Rolling Share Option Plan the maximum number of common shares which can be reserved for issuance is 10% of the issued and outstanding shares of the Company. The minimum exercise price of the options shall not be less than the price determined in accordance with CSE policies while the Company's shares are listed on the CSE. Options granted may be subject to vesting provisions as determined by the Board of Directors and have a maximum term of ten years.

During the nine months ended August 31, 2022 the Company granted share options to purchase 200,000 (2021 - 8,200,000) common shares and recorded share-based compensation expense of \$367,963 (2021 - \$2,064,509) on the vesting of share options granted.

The fair value of share options granted and vested during the nine months ended August 31, 2022 and 2021 was estimated using the Black-Scholes Option Pricing Model using the following assumptions:

	<u>2022</u>	<u>2021</u>
Risk-free interest rate	0.62% - 1.59%	0.88% - 0.90%
Estimated volatility	75% - 115%	112% - 123%
Expected life	0.5 year - 4 years	1 year - 5 years
Expected dividend yield	0%	0%
Estimated forfeiture rate	0%	0%

The weighted average measurement date fair value of all share options granted and vested during the nine months ended August 31, 2022, using the Black-Scholes Option Pricing Model, was \$0.09 (2021 - \$1.02) per option.

Option-pricing models require the use of estimates and assumptions including the expected volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measure of the fair value of the Company's share options.

A summary of the Company's share options at August 31, 2022 and 2021 and the changes for the nine months ended on those dates is as follows:

	20	122	2021		
	Number of Options Outstanding	Weighted Average Exercise Price \$	Number of Options Outstanding	Weighted Average Exercise Price \$	
Balance, beginning of period	8,200,000	0.58	-	-	
Granted	200,000	0.60	8,200,000	0.58	
Expired	(500,000)	0.88		-	
Balance, end of period	7,900,000	0.56	8,200,000	0.58	

The following table summarizes information about the share options outstanding and exercisable at August 31, 2022:

Number Outstanding	Number Exercisable	Exercise Price \$	Expiry Date
7,700,000	5,775,000	0.56	February 26, 2026
200,000		0.60	January 5, 2024
7,900,000	5,775,000		

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

9. Share Capital (continued)

(g) Deferred Share Unit ("DSU") Plan and Restricted Share Unit ("RSU") Plan

On January 27, 2021 the Company issued 125,000 common shares of the Company on the partial redemption of DSUs by a former director of the Company, with the remaining 75,000 DSUs cancelled.

On February 26, 2021 the Company's Board of Directors approved a rolling restricted share unit plan (the "RSU Plan") as a replacement for the Company's DSU plan. Under the RSU Plan the maximum number of restricted shares units ("RSUs") which can be awarded is 10% of the issued and outstanding common shares of the Company. RSUs awarded may be subject to vesting provisions as determined by the Board of Directors. The remaining 1,550,000 DSUs outstanding were transferred to the RSU Plan, with equivalent and no additional vesting, subject to the terms and provisions of the RSU Plan. Under IFRS 2, *Share-based Payment*, the transferring of the DSUs into RSUs are considered to be a modification and the Company has recognized additional share-based compensation expense of \$337,250 during fiscal 2021.

A summary of the Company's DSUs is as follows:

	DSUs
Balance as at November 30, 2020	1,250,000
Awarded	500,000
Redeemed	(125,000)
Cancelled	(75,000)
Transferred to RSU Plan	(1,550,000)
Balance as at November 30, 2021	-

Number of

During fiscal 2021 the Company awarded 9,470,000 RSUs, of which 1,300,000 RSUs vested immediately and the remaining 8,170,000 RSUs are subject to vesting over two years. During the nine months ended August 31, 2022 the Company recognized \$1,429,891 (2021 - \$2,205,578) as share-based compensation expense relating to awarding and vesting of the RSUs.

A summary of the Company's RSUs is as follows:

	Number of RSUs
Balance as at November 30, 2021	10,020,000
Awarded	400,000
Redeemed	(1,000,000)
Balance as at August 31, 2022	9,420,000

The following table summarizes information about the RSUs outstanding and exercisable at August 31, 2022:

Number Outstanding	Number Exercisable
7,900,000	4,375,000
1,120,000	620,000
400,000	200,000
9,420,000	5,195,000

See also Note 14(ii).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

10. Interest Expense and Financing Costs

	August 31, 2022	August 31, 2021
	\$	\$
Interest on Revised Sapientia Obligation (Note 7(a))	136,982	-
Interest on Amara Promissory Note (Note 7(b))	799,745	-
Cortland Facility financing transaction costs (Note 8)	692,250	285,000
Interest on Cortland Facility (Note 8)	2,750,409	276,617
	4,379,386	561,617

11. Related Party Disclosures

- (a) Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consists of members of the Company's Board of Directors and executive officers.
 - (i) During the nine months ended August 31, 2022 and 2021 the following amounts were incurred with respect to these positions:

	2022	2021
	\$	\$
Directors and officers compensation	1,423,830	219,775
Benefits	123,308	8,696
Share-based compensation on share options	255,789	485,476
Share-based compensation on DSUs	-	41,484
Share-based compensation on RSUs	280,223	751,123
Share-based compensation on transferring DSUs to RSUs		313,500
	2,083,150	1,820,054

As at August 31, 2022, \$nil (November 30, 2021 - \$13,432) remained unpaid and has been included in accounts payable and accrued liabilities.

(ii) During the nine months ended August 31, 2022 the Company incurred a total of \$84,500 (2021 - \$43,800) by Chase Management Ltd. ("Chase"), a private corporation owned by the former Chief Financial Officer ("CFO"), for accounting and administration services provided by Chase personnel, excluding the former CFO. As at August 31, 2022 \$4,000 (November 30, 2021 - \$20,000) remained unpaid and has been included in accounts payable and accrued liabilities.

During the nine months ended August 31, 2021 the Company recorded \$137,495 share-based compensation for share options, DSUs and RSUs granted to Chase.

- (iii) During the nine months ended August 31, 2022 the Company incurred a total of \$302,876 (2021 \$nil) by Dunn, Pariser & Peyrot ("Dunn"), a private corporation owned by the CFO, for accounting and administration services provided by Dunn.
- (iv) During the nine months ended August 31, 2022 the Company incurred a total of \$813,108 (2021 \$nil) by McMillan LLP ("McMillan"), a law firm, of which a Director of the Company is a partner of McMillan, for legal services. As at August 31, 2022 \$667,680 (November 30, 2021 \$436,723) remained unpaid and has been included in accounts payable and accrued liabilities.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

11. Related Party Disclosures (continued)

(b) The Company has made advances to Rockshield Opportunities Corp. ("Rockshield Opportunities") a company which was initially incorporated as a wholly-owned subsidiary of the Company and of which its common shares were subsequently distributed to the Company shareholders. The advances are non-interest bearing and repayable on demand. As at August 31, 2022, \$16,500 (November 30, 2021 - \$16,500) is outstanding. A former director of the Company is also a director of Rockshield Opportunities.

12. Financial Instruments and Risk Management

Categories of Financial Assets and Financial Liabilities

Financial instruments are classified into one of the following categories: FVTPL; amortized cost; and FVOCI. The carrying values of the Company's financial instruments are classified into the following categories:

Financial Instrument	Category	August 31, 2022 \$	November 30, 2021 \$
Cash	Amortized cost	2,461,665	545,976
Advances receivable	Amortized cost	16,500	16,500
Investments in marketable securities	FVTPL	373,900	634,846
Private investments	FVTPL	59,755,080	54,755,080
Loans receivable	Amortized cost	1,080,648	2,423,922
Accounts payable and accrued liabilities	Amortized cost	(1,003,560)	(668,153)
Loans payable	Amortized cost	(9,806,266)	(16,483,723)
Credit facility	Amortized cost	(38,881,412)	(33,205,342)

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Fair Value

The fair values of the Company's financial assets and liabilities approximates the carrying amounts either due to their short-term nature or because the interest rates applied to measure their carrying amount approximate current market rates.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.
- Level 2 Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the market place.
- Level 3 Valuations in this level are those with inputs for the asset or liability that are not based on observable market

The recorded amounts for cash, advances receivable, accounts payable and accrued liabilities, loans payable and credit facility approximate their fair value due to their short-term nature. The recorded amounts for investments in marketable securities, private investments, at fair value through profit or loss, and loans receivable approximate their fair value. The fair value of investment in marketable securities under the fair value hierarchy is measured using Level 1 and Level 3 inputs. The fair value of private investments, at fair value through profit or loss, and loans receivable are measured using level 3 inputs.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

12. Financial Instruments and Risk Management (continued)

(i) Valuation techniques used to determine fair values

Specific valuation techniques used to fair value financial instruments, specifically those that are not quoted in an active market. Plant-Based News Limited, Belle Pulses, Sapientia and Amara are private companies not traded on any public exchange and are considered level 3 assets because there is no market in which a share price can be readily observed. These are start up and development stage companies and, as such, the Company utilized a market approach:

- (a) The use of quoted market prices in active or other public markets
- (b) The use of most recent transactions of similar instruments
- (c) Changes in expected operational milestones of the investee
- (d) Changes in management, strategy, litigation matters or other internal matters
- (e) Significant changes in the results of the investee compared with the budget, plan, or milestone
- (ii) Transfers between levels 2 and 3

There were no transfers between levels 2 and 3 during the nine months ended August 31, 2022 and 2021.

(iii) Valuation inputs and relationships to fair value

The following table summarises the quantitative information about the significant unobservable inputs used in the level 3 fair value measurements (see above for valuation techniques adopted):

	Fair	Value	Unobservable Inputs	Range of Inputs
Description	August 31, 2022 \$	November 30, 2021 \$	August 31, 2022 \$	August 31, 2022 \$
Plant-Based News Limited	175,444	175,444	Timeline for milestones	N/A
Belle Pulses	35,000,000	30,000,000	Timeline for milestones	N/A
Sapientia	10,374,680	10,374,680	Timeline for milestones	N/A
Amara	14,380,400	14,380,400	Timeline for milestones	N/A
	59,930,524	54,930,524		

(iv) Valuation processes

The Investment Committee includes a team that performs the valuations of all items required for financial reporting purposes, including level 3 fair values. This team collaborates with the CFO and the audit committee ("AC"). Discussions of valuation processes and results are held between the CFO, AC and the valuation team at least once every three months which is in-line with the Company's reporting requirements. The main Level 3 inputs derived and evaluated by the Company's team are the timeline for expected milestones and assessment of the technical matter relating to the technology.

The Company performed a sensitivity analysis on the carrying value of its Level 3 assets and noted that a 20% decrease would result in an approximately \$11,986,000 decrease in fair value.

Credit Risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, advances receivable and loans receivable. Management believes that the credit risk concentration with respect to financial instruments included in cash and advances receivable is remote. The Company mitigates its credit risk in loans receivable by only providing loans to companies where it has detailed knowledge of the company's operations and business strategy.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

12. Financial Instruments and Risk Management (continued)

Liquidity Risk

Liquidity risk is the risk that the Company will not have the resources to meet its obligations as they fall due. The Company manages this risk by closely monitoring cash forecasts and managing resources to ensure that it will have sufficient liquidity to meet its obligations. All of the Company's financial liabilities are classified as current and are anticipated to mature within the next fiscal period. The Company anticipates that it will need to secure additional funding to retire its indebtedness as they come due, or in the alternative, renegotiate terms of payment. The following table is based on the contractual maturity dates of financial assets and the earliest date on which the Company can be required to settle financial liabilities.

		Contractual Ma	nturity Analysis at Au	ıgust 31, 2022	
	Less than 3 Months \$	3 - 12 Months \$	1 - 5 Years \$	Over 5 Years \$	Total \$
Cash	2,461,665	-	-	-	2,461,665
Advances receivable	16,500	-	-	-	16,500
Accounts payable and accrued liabilities	(1,003,560)	-	-	-	(1,003,560)
Loans payable	(1,741,937)	(5,612,762)	(2,451,567)	-	(9,806,266)
Credit facility	(391,412)	(38,490,000)	-	-	(38,881,412)
	Contractual Maturity Analysis at November 30, 2021				
		Contractual Mat	urity Analysis at Nov	ember 30, 2021	
	Less than 3 Months	Contractual Mate	urity Analysis at Nov 1 - 5 Years \$	Over 5 Years	Total \$
Cash	3 Months	3 - 12 Months	1 - 5 Years	Over 5 Years	
Cash Advances receivable	3 Months \$	3 - 12 Months	1 - 5 Years	Over 5 Years	\$
	3 Months \$ 545,976	3 - 12 Months	1 - 5 Years	Over 5 Years	\$ 545,976
Advances receivable	3 Months \$ 545,976 16,500	3 - 12 Months	1 - 5 Years	Over 5 Years	\$ 545,976 16,500

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates and commodity and equity prices. These fluctuations may be significant.

(a) Interest Rate Risk

The Company is exposed to interest rate risk to the extent that the cash and demand deposits bear floating rates of interest. The interest rate risk on cash, loans receivable and loans payable are not considered significant.

(b) Market Risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate because of changes in market prices. The Company is exposed to market risk in trading its investments and unfavorable market conditions could result in dispositions of investments at less than favorable prices.

As of August 31, 2022, \$60,835,728 of the Company's investments in and loans to plant-based companies represents approximately 95% of the Company's total assets and poor performance in these investments could adversely affect the Company's results.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

12. Financial Instruments and Risk Management (continued)

(c) Foreign Currency Risk

The Company's functional currency is the Canadian Dollar. The Company maintains a US Dollar bank account to support the cash needs of its US operations. Management does not hedge its foreign exchange risk. As of August 31, 2022, 1 Canadian Dollar was equal to 0.76 US Dollar.

Balances are as follows:

	US Dollars	CDN \$ Equivalent
Cash	387,482	509,845
Loans receivable	689,084	906,689
Accounts payable and accrued liabilities	(121,319)	(159,630)
Loans payable	(7,466,660)	(9,806,266)
	(6,511,413)	(8,549,362)

Based on the net exposures as of August 31, 2022 and, assuming that all other variables remain constant, a 10% fluctuation on the Canadian Dollar against the US Dollar would result in the Company's net loss being approximately \$841,000 higher (or lower).

Capital Management

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support its investments. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital that it manages as share capital and amounts borrowed under the Credit Facility. The Company will continue to assess new investment opportunities as they arise and if it has adequate financial resources to do so. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

13. Supplemental Cash Flow Information

During the nine months ended August 31, 2022 and 2021 non-cash activities were conducted by the Company as follows:

	2022 \$	2021 \$
Operating activities		
Financing costs	-	(825,000)
Transaction costs	-	(11,189,012)
Investment in private investments	-	(7,946,340)
Accounts payable and accrued liabilities		(33,000)
		(19,993,352)
Financing activities		
Amounts due	-	5,551,480
Issuance of share capital	789,085	14,188,943
Share issue costs	(177,815)	(266,275)
Subscriptions received in advance	(239,085)	_
Share-based payments reserve	(372,185)	519,204
	_	19,993,352

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED AUGUST 31, 2022

(Unaudited - Expressed in Canadian Dollars)

14. Events after the Reporting Period

Subsequent to August 31, 2022 the Company:

- (i) repurchased 16,500 common shares for \$3,735 cash consideration under the Second NCIB;
- (ii) issued 200,000 common shares on the exercise of RSUs;
- (iii) paid US \$1,325,000 of quarterly principal on the Amara Promissory Note and US \$3,607 of accrued interest;
- (iv) made a further advance of US \$50,000 to Sapientia; and
- (v) Belle Pulses repaid the remaining \$41,000 of principal of the Belle Pulses Loan and \$136,494 of accrued interest. In addition Belle Pulses loaned \$922,506 to the Company, with the terms and conditions to be negotiated.